Shomik Sengupta

Prof. Shomik Sengupta

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in Cancer Research
Verified
Journal Article
Open access
PDF file
RTR. Houston Thompson
R. Houston Thompson
SKSusan M. Kuntz
Susan M. Kuntz
BLBradley C. Leibovich
Bradley C. Leibovich
HDHaidong Dong
Haidong Dong
CLChristine M. Lohse
Christine M. Lohse
EKEugene D. Kwon
Eugene D. Kwon
B7-H1 participates in T-cell costimulation functioning as a negative regulator of immunity. Recent observations suggest that B7-H1 is expressed by renal cell carcinoma (RCC) tumor cells and is associated with poor prognosis. However, outcome analyses have been restricted to patients with fresh-frozen tissue and limited follow-up. We report the clinical effect of B7-H1 in RCC patients with a median of 10 years of follow-up. Between 1990 and 1994, 306 patients underwent nephrectomy for clear cell RCC and had paraffin tissue available for review. We did immunohistochemistry with anti-B7-H1 and conducted outcome analyses. Among the 306 patients, 73 (23.9%) harbored tumors with B7-H1 expression. Patients with tumor B7-H1 were at a significantly increased risk of both death from RCC [risk ratio (RR), 3.92; P < 0.001] and overall mortality (RR, 2.37; P < 0.001). The 5-year cancer-specific survival rates were 41.9% and 82.9% for patients with and without tumor B7-H1, respectively. In a multivariate model, tumor B7-H1 remained associated with cancer-specific death even after adjusting for tumor-node-metastasis stage, grade, and performance status (RR, 2.00; P = 0.003). In the subset of 268 patients with localized RCC, tumor B7-H1 was significantly associated with metastatic cancer progression (RR, 3.46; P < 0.001) and death from RCC (RR, 4.13; P < 0.001) even after adjusting for stage, grade, and performance status (RR, 1.78, P = 0.036). RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor. (Cancer Res 2006; 66(7): 3381-5)

29 November 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RTR. Houston Thompson
R. Houston Thompson
MGMichael D. Gillett
Michael D. Gillett
JCJohn C. Cheville
John C. Cheville
CLChristine M. Lohse
Christine M. Lohse
HDHaidong Dong
Haidong Dong
EKEugene D. Kwon
Eugene D. Kwon
Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to macrophage-lineage cells, providing a potential costimulatory signal source for regulation of T cell activation. In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. The relationship between tumor-associated B7-H1 and clinical cancer progression is unknown. Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. In fact, patients with high tumor and/or lymphocyte B7-H1 levels are 4.5 times more likely to die from their cancer than patients exhibiting low levels of B7-H1 expression (risk ratio 4.53; 95% confidence interval 1.94–10.56;P< 0.001.) Thus, our study suggests a previously undescribed mechanism whereby RCC may impair host immunity to foster tumor progression. B7-H1 may prove useful as a prognostic variable for RCC patients both pre- and posttreatment. In addition, B7-H1 may represent a promising target to facilitate more favorable responses in patients who require immunotherapy for treatment of advanced RCC.

1 April 2019 in European Urology
Verified
Journal Article
Closed access
SLStacy Loeb
Stacy Loeb
SSShomik Sengupta
Shomik Sengupta
MBMohit Butaney
Mohit Butaney
JMJoseph N. Macaluso
Joseph N. Macaluso
SCStefan W. Czarniecki
Stefan W. Czarniecki
ALAisha Langford
Aisha Langford

22 June 2005 in Cancer
Verified
Journal Article
Open access
PDF file
SSShomik Sengupta
Shomik Sengupta
CLChristine M. Lohse
Christine M. Lohse
BLBradley C. Leibovich
Bradley C. Leibovich
IFIgor Frank
Igor Frank
RTR. Houston Thompson
R. Houston Thompson
EKEugene D. Kwon
Eugene D. Kwon
BACKGROUND: Prognostic markers for renal cell carcinoma (RCC), such as patient symptoms, tumor stage, tumor size, and tumor grade, are useful for determining appropriate follow‐up and selecting patients for adjuvant therapy. Histologic coagulative tumor necrosis, also reported to be a prognostic marker for RCC, has not previously been extensively described or investigated. Hence, the objective of the current study was to characterize tumor necrosis as a prognostic feature of RCC.METHODS: The authors of the current study identified 3009 patients treated surgically for RCC between 1970 and 2002 from the Mayo Clinic Nephrectomy Registry (Rochester, MN). Associations of tumor necrosis with clinical, laboratory, and pathologic features were examined with chi‐square, Fisher exact test, and Wilcoxon rank‐sum tests. Cancer‐specific survival was estimated with the Kaplan–Meier method, and associations with outcome were assessed with Cox proportional hazard models.RESULTS: Tumor necrosis was present in 690 of 2445 (28%) clear cell, 196 of 421 (47%) papillary, and 28 of 143 (20%) chromophobe RCCs. The risk ratio for death from RCC in patients with necrotic compared with nonnecrotic tumors was 5.27 (95% confidence interval [CI]: 4.56–6.09; P < 0.001) for clear cell, 4.20 (CI: 1.65–10.68; P < 0.001) for chromophobe, and 1.49 (CI: 0.81–2.74; P = 0.199) for papillary RCC. The survival difference for clear cell RCC persisted even after multivariate adjustment for tumor stage, size, and grade (risk ratio 1.90; P < 0.001).CONCLUSIONS: Histologic coagulative tumor necrosis is an independent predictor of outcome for clear cell and chromophobe RCC, and it should be routinely reported and used in clinical assessment. Cancer 2005. © 2005 American Cancer Society.

1 April 2007 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SSSameer A. Siddiqui
Sameer A. Siddiqui
XFXavier Frigola
Xavier Frigola
SBSandra Bonne-Annee
Sandra Bonne-Annee
MMMaria Mercader
Maria Mercader
SKSusan M. Kuntz
Susan M. Kuntz
EKEugene D. Kwon
Eugene D. Kwon
Purpose: Regulatory T cells (Tregs) have been implicated as inhibitors of antitumoral immunity, and evidence suggests that elimination of Tregs may augment natural and pharmacologic immunity. We tested for the presence of putative Tregs within renal cell carcinoma (RCC) tumors. Experimental Design: We identified 170 patients who underwent radical or partial nephrectomy for clear cell RCC between 2000 and 2002. Specimens were stained with anti-CD4, anti-CD25, and anti-Foxp3 antibodies and examined using confocal microscopy. Associations of CD4+CD25+Foxp3− and CD4+CD25+Foxp3+ T cells with death from RCC were evaluated using Cox proportional hazards regression models. Results: At last follow-up, 46 of 170 patients had died; of these, 37 died from RCC at a median of 1.4 years following nephrectomy (range, 0-4.4). Among the 124 remaining patients, median follow-up was 3.7 years (range, 0-5.7). Forty-three (25.3%) tumors harbored CD4+CD25+Foxp3+ T cells. The presence of Foxp3+ T cells was not significantly associated with RCC death univariately. One hundred forty-three (84.1%) tumors harbored CD4+CD25+Foxp3− T cells. The indicator for ≥10% CD4+CD25+Foxp3− T cells was significantly associated with RCC death univariately [risk ratio (RR), 2.60; 95% confidence interval (95% CI), 1.35-4.98; P = 0.004], after adjusting for tumor B7-H1 expression (RR, 2.53; 95% CI, 1.32-4.85; P = 0.005) and lymphocytic infiltration (RR, 2.53; 95% CI, 1.32-4.87; P = 0.005). Conclusions: Increased presence of CD4+CD25+Foxp3+ T cells was not significantly associated with RCC death. In contrast, CD4+CD25+Foxp3− T cells, which may represent a unique set of Tregs or activated helper T cells, was significantly associated with outcome.

1 January 2006 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SSShomik Sengupta
Shomik Sengupta
JMJane G Muir
Jane G Muir
PGPeter R Gibson
Peter R Gibson